Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: -22.55%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a company in transition, highlighting strong growth prospects for LOQTORZI and promising clinical developments. However, challenges in market penetration and short-term revenue impacts due to restructuring were noted. Despite these challenges, the strategic focus on oncology and potential cost savings are positive indicators for future performance.Company Guidance
During the Coherus BioSciences Q1 2025 earnings call, key guidance focused on the company's strategic shift to an innovative oncology business, highlighted by the FDA-approved PD-1 inhibitor LOQTORZI. The company projects LOQTORZI sales in nasopharyngeal carcinoma (NPC) to grow to $150 million to $200 million annually over the next three years, with a breakeven point of $15 million per quarter to cover commercial costs. Coherus is executing an indication expansion strategy for LOQTORZI, with multiple partnerships and pivotal trials in place to broaden its use across different cancer types. The call also emphasized the ongoing development of CHS-114 and casdozokitug, with clinical data readouts expected in 2025 supporting the advancement of these candidates. The company anticipates annualized savings of $25 million from headcount reductions following the UDENYCA divestiture and projects SG&A expenses for 2025 to be between $90 million and $100 million.LOQTORZI Growth Prospects
LOQTORZI is projected to grow to about $150 million to $200 million annually over the next three years, providing non-dilutive funding for the development pipeline and becoming an important revenue source as indications expand.
Positive Clinical Developments
CHS-114 showed a 40% reduction in target lesions in a late-line head and neck cancer patient, indicating potential to address PD-1 resistance. Additionally, a 17% complete response rate was observed in a liver cancer trial with casdozokitug.
Strategic Partnerships and Indication Expansion
Several agreements are in place to expand indications for toripalimab, including collaborations with INOVIO for HPV-positive head and neck cancer, and Junshi for small cell lung cancer.
Successful Restructuring and Cost Savings
The company expects $25 million in annualized savings from a reduced headcount post-UDENYCA divestiture, with more than half already realized.
CHRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CHRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $1.02 | $0.82 | -19.61% |
Mar 10, 2025 | $1.04 | $1.05 | +0.96% |
Nov 06, 2024 | $0.72 | $0.82 | +13.89% |
Aug 08, 2024 | $1.29 | $1.43 | +10.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Coherus Biosciences (CHRS) report earnings?
Coherus Biosciences (CHRS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Coherus Biosciences (CHRS) earnings time?
Coherus Biosciences (CHRS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHRS EPS forecast?
CHRS EPS forecast for the fiscal quarter 2025 (Q2) is -0.26.